Immunotherapy for Leukemia: Harnessing the Body’s Defenses Against Blood Cancer
Explore how advanced immunotherapy treatments are transforming leukemia care and empowering the immune system to defeat cancer.
Immunotherapy represents a major evolution in the treatment of leukemia, offering new options for patients by leveraging the power of the body’s own immune system. Unlike conventional treatments such as chemotherapy or radiation, immunotherapies are designed to educate and activate immune cells specifically to seek and destroy leukemia cells, which often evade normal immune surveillance. In this article, we explore the main types of immunotherapy used in leukemia, how they work, their benefits and risks, and what patients can expect from these innovative therapies.
What Is Immunotherapy?
Immunotherapy refers to a category of treatments that enhance or restore the ability of the immune system to fight cancer. Normally, the immune system works to protect us against infections and abnormal cells, but leukemia cells can disguise themselves or suppress immune responses, permitting the cancer to grow unchecked. Immunotherapy treatments aim to reverse this, helping immune cells recognize and attack leukemia more effectively.
- Direct activation of immune cells to kill cancer.
- Blocking cancer cells’ defenses that hide them from immune attack.
- Targeting specific markers on leukemia cells for destruction.
How Immunotherapy Treats Leukemia
The immune system includes highly specialized white blood cells—B-lymphocytes and T-lymphocytes—that play distinct roles in defending the body. While these cells are effective against foreign bacteria and viruses, leukemia originates from white blood cells, allowing cancer cells to masquerade as healthy cells. Immunotherapy offers new strategies for overcoming these disguises:
- Modification of immune cells to recognize and kill leukemia.
- Restoration of normal immune function through lab-made substances.
- Interruption of signals that cancer cells use to avoid detection.
Depending on the drug and method, immunotherapy may be used:
- As first-line or secondary treatment.
- In combination with chemotherapy or radiation.
- As maintenance therapy to reduce relapse risk.
Types of Immunotherapy for Leukemia
There are several key immunotherapy methods utilized in leukemia care. The main ones include:
- Chimeric antigen receptor (CAR) T-cell therapy
- Donor lymphocyte infusion
- Monoclonal antibodies
- Immune checkpoint inhibitors
CAR T-cell Therapy
CAR T-cell therapy is among the most revolutionary advances for blood cancers. In this approach, doctors extract T-cells from the patient’s blood and genetically re-engineer them in the laboratory to express special chimeric antigen receptors (CARs) on their surface. These receptors are designed to recognize specific markers on leukemia cells. Once infused back into the patient, these supercharged CAR T-cells hunt down and destroy cancer:
- T-cells are harvested from the patient.
- CAR proteins are introduced via genetic engineering.
- Modified cells are multiplied and returned by infusion.
- The CAR T-cells seek leukemia cells and initiate destruction.
Benefits:
- Precise targeting with high effectiveness, particularly in acute lymphoblastic leukemia (ALL).
- Can induce remission even in cases refractory to other therapies.
Risks & Limitations:
- Cytokine release syndrome (CRS) – an overreaction of the immune system leading to fever, low blood pressure, or organ dysfunction.
- Neurotoxicity – confusion, seizures, or weakness.
- Not suitable for all patients; eligibility based on age, cancer subtype, and prior treatments.
Donor Lymphocyte Infusion (DLI)
Donor lymphocyte infusion is mainly used in patients with chronic myeloid leukemia (CML) or those who relapse after allogeneic stem cell transplantation. In DLI, T-cells are taken from the original stem cell donor and infused into the patient.
What others are reading
- The donor T-cells produce a graft-versus-tumor (GVT) effect, attacking residual leukemia cells.
- DLI may induce remission in patients who did not respond to transplant alone.
Drawbacks:
- Graft-versus-host disease (GVHD) – donor cells may attack normal tissues.
Monoclonal Antibodies
Monoclonal antibodies are engineered proteins that mimic the body’s natural immune defenders. They are tailored to latch onto specific molecules found on leukemia cells (such as CD19, CD20, or CD33), marking them for destruction. These drugs are generally delivered intravenously:
- Antibodies attach to leukemia-specific markers.
- The attached leukemia cell becomes recognizable to immune cells.
- Monoclonal antibodies may also block cell-signaling processes needed for cancer cell growth.
Some monoclonal antibodies are conjugated—linked to chemotherapy agents or radioactive particles for additional killing power.
| Antibody Name | Target | Leukemia Type |
|---|---|---|
| Blinatumomab | CD19 (BiTE agent) | ALL |
| Rituximab | CD20 | CLL |
| Gemtuzumab ozogamicin | CD33 | AML |
Immune Checkpoint Inhibitors
Leukemia cells can manipulate immune checkpoints—molecular switches that turn immune responses off and on. Checkpoint inhibitors are monoclonal antibodies that block leukemia cells from flipping these switches off, so immune cells remain active:
- Block inhibitory signals used by cancer to hide from T-cells.
- Restores immune ability to recognize and kill leukemia cells.
Checkpoint inhibitors have shown promise in some leukemia subtypes and as part of combination approaches.
When Is Immunotherapy Used in Leukemia?
Immunotherapy can play a role at various stages of leukemia management:
- Initial treatment: For some patients, especially those with certain ALL (acute lymphoblastic leukemia) or AML (acute myeloid leukemia) subtypes, immunotherapy may be a first-line option.
- Relapsed or refractory disease: When leukemia does not respond to chemotherapy or returns after remission, immunotherapy provides new hope.
- Maintenance therapy: To minimize the risk of recurrence following successful initial treatment.
- Combination therapies: Used alongside chemotherapy, radiation, or targeted drugs for more robust results.
Potential Benefits of Immunotherapy
- Precision targeting avoids some of the damage done to healthy cells by chemotherapy and radiation.
- Remission rates can be higher for relapsed cancers.
- Reduced toxicity in certain patients compared to traditional therapies.
- Expanding options for those who are ineligible for aggressive chemotherapy due to age or poor health.
Possible Risks and Side Effects
Despite its promise, immunotherapy can cause significant and sometimes severe side effects. These may include:
- Cytokine release syndrome (CRS): A rapid immune response causing fever, chills, low blood pressure, and organ problems.
- Neurotoxicity: Confusion, seizures, or muscle weakness.
- Graft-versus-host disease (GVHD): With donor cell therapies, risk of immune attack against healthy tissue.
- Autoimmune reactions: Overactive immune response targeting normal cells.
Doctors monitor patients closely and may use supportive drugs to manage side effects.
How to Prepare for Immunotherapy
- Detailed medical evaluation to determine eligibility.
- Blood tests and genetic profiling to identify markers suitable for targeted therapies.
- Consultation with a hematologist/oncologist specializing in immunotherapies.
- Discussion of risks, outcomes, and supportive care measures.
Patients should inform their care team of all medications, allergies, and pre-existing conditions to ensure safe administration and to personalize side effect management.
Frequently Asked Questions (FAQs)
Q: How does immunotherapy differ from chemotherapy in treating leukemia?
A: Immunotherapy harnesses the immune system to recognize and destroy leukemia cells, while chemotherapy uses cytotoxic compounds to kill rapidly-dividing cells, both healthy and cancerous. Immunotherapy aims for more precise targeting and may have fewer systemic side effects.
Q: Who qualifies for CAR T-cell therapy?
A: CAR T-cell therapy is typically reserved for patients with relapsed or refractory acute lymphoblastic leukemia who have not responded to standard treatments. Eligibility depends on the cancer type, age, overall health, and availability of suitable immune markers.
Q: Are immunotherapy drugs used alone or with other treatments?
A: Immunotherapies may be administered alone in certain cases, but are often combined with chemotherapy, targeted therapy, or stem cell transplantation to maximize treatment effectiveness.
Q: What are the major risks associated with immunotherapy for leukemia?
A: Key risks include immune system overreaction (cytokine release syndrome), neurotoxicity, autoimmune reactions, and in the case of donor cell therapies, graft-versus-host disease.
Q: Can immunotherapy cure leukemia?
A: Immunotherapy can induce lasting remission in some patients, particularly with acute lymphoblastic leukemia, and is considered curative in select cases. However, many patients require ongoing monitoring or combination treatment to maintain remission.
Looking Ahead: Research and Emerging Therapies
Immunotherapy is the fastest-growing frontier in leukemia treatment. Ongoing clinical trials are investigating new immune-modulating drugs, combination regimens, and innovative delivery methods to optimize safety and efficacy. Areas of active research include:
- Next-generation CAR T-cell engineering to reduce side effects.
- Bispecific antibodies that engage both cancer and immune cells for enhanced killing.
- Personalized therapy based on molecular profiling and genetic markers.
- Immunotherapy for additional leukemia subtypes such as AML, CML, and chronic lymphocytic leukemia (CLL).
With continued advances, immunotherapy offers hope for improving outcomes, extending survival, and ultimately redefining standards of care for leukemia patients worldwide.
References
- https://leukemiarf.org/patients/treatment/options/immunotherapy/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC9619355/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC10453133/
- https://www.moffitt.org/cancers/leukemia/treatment/immunotherapy/
- https://www.cancer.org/cancer/types/acute-lymphocytic-leukemia/treating/monoclonal-antibodies.html
- https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1505247/full
- https://www.cancerresearchuk.org/about-cancer/acute-lymphoblastic-leukaemia-all/treatment/targeted-cancer-drugs-and-immunotherapy-all
- https://www.roswellpark.org/cancer/leukemia/treatment/immunotherapy
Similar Articles
Read full bio of Sneha Tete
